LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
The Treaty on European Union (TEU) and the Treaty on the Functioning of the European Union (TFEU) are the two main sources of EU law. Representing agreements between all member states, the TEU focuses more on principles of democracy, human rights, and summarises the institutions, while the TFEU expands on all principles and fields of policy in which the EU can legislate. In principle, the EU treaties are like any other international agreement, which will usually be interpreted according to principles codified by the Vienna Convention 1969. It can be amended by unanimous agreement at any time, but TEU itself, in article 48, sets out an amendment procedure through proposals via the Council and a Convention of national Parliament representatives. Under TEU article 5(2), the "principle of conferral" says the EU can do nothing except the things which it has express authority to do. The limits of its competence are governed by the Court of Justice, and the courts and Parliaments of member states. Under TEU article 6(1), the Charter of Fundamental Rights of the European Union (CFR) has the same legal value as the Treaties (TEU & TFEU). It does not, however, extend the competences of the EU. It serves as a set of fundamental rights which all EU legislation has to respect, whether it is an EU institution or a member state which executes those laws. As the European Union has grown from 6 to 27 member states, a clear procedure for accession of members is set out in TEU article 49.
In clitoridectomy, the clitoris may be removed as part of a radical vulvectomy to treat cancer such as vulvar intraepithelial neoplasia; however, modern treatments favor more conservative approaches, as invasive surgery can have psychosexual consequences. Clitoridectomy more often involves parts of the clitoris being partially or completely removed during FGM, which may be additionally known as female circumcision or female genital cutting (FGC). Removing the glans does not mean that the whole structure is lost, since the clitoris reaches deep into the genitals. In reduction clitoroplasty, a common intersex surgery, the glans is preserved and parts of the erectile bodies are excised. Problems with this technique include loss of sensation, loss of sexual function, and sloughing of the glans. One way to preserve the clitoris with its innervations and function is to imbricate and bury the glans; however, Şenaylı et al. state that "pain during stimulus because of trapped tissue under the scarring is nearly routine. In another method, 50 percent of the ventral clitoris is removed through the level base of the clitoral shaft, and it is reported that good sensation and clitoral function are observed in follow-up"; additionally, it has "been reported that the complications are from the same as those in the older procedures for this method".
== Medical devices == A variety of medical devices are in use or under consideration for treatment of depression including devices that offer electroconvulsive therapy, vagus nerve stimulation, repetitive transcranial magnetic stimulation, and cranial electrotherapy stimulation. The use of such devices in the United States requires approval by the U.S. Food and Drug Administration (FDA) after field trials. In 2010 an FDA advisory panel considered the question of how such field trials should be managed. Factors considered were whether drugs had been effective, how many different drugs had been tried, and what tolerance for suicides should be in field trials.
Entourage Guimard: Square-Victoria–OACI station on the Montreal Metro in Canada has a genuine Guimard entrance made from parts of demolished Paris entrances (with map holder and "Métropolitain" sign and holder reproduced from the original molds). It was installed in 1967. During restoration in 2001–2002, it was found to have the last examples of the original glass light globes, which in Paris had been replaced with plastic for safety; one was returned to the RATP and the other placed on display in the Montreal Museum of Fine Arts. Bellas Artes station on the Mexico City Metro in Mexico has a Guimard entrance installed in 1998. Picoas station on the Lisbon Metro in Portugal has a Guimard entrance installed in 1995. Kievskaya station on the Moscow Metro in Russia has a Guimard entrance installed in 2007. Van Buren Street station on the Metra Electric District in Chicago had a Guimard entrance installed in 2001. An Entrance to the Paris Métropolitain: The National Gallery of Art in Washington, D.C., United States has a Guimard entrance in its sculpture garden, first shown at the gallery in a 2000–2001 exhibition on Art Nouveau and permanently installed in the garden in 2003. The Museum of Modern Art in New York City, United States has the archway consisting of the light stalks and "Métropolitain" sign from the Guimard entrance to Raspail station. The Dali Theater Museum in Figueres (Girona, Spain) has a pair of the light stalks from a Guimard Métro entrance, which are exhibited on the patio.
In continuous-flow solution culture, the nutrient solution constantly flows past the roots. It is much easier to automate than the static solution culture because sampling and adjustments to the temperature, pH, and nutrient concentrations can be made in a large storage tank that has potential to serve thousands of plants. A popular variation is the nutrient film technique or NFT, whereby a very shallow stream of water containing all the dissolved nutrients required for plant growth is recirculated in a thin layer past a bare root mat of plants in a watertight channel, with an upper surface exposed to air. As a consequence, an abundant supply of oxygen is provided to the roots of the plants. A properly designed NFT system is based on using the right channel slope, the right flow rate, and the right channel length. The main advantage of the NFT system over other forms of hydroponics is that the plant roots are exposed to adequate supplies of water, oxygen, and nutrients. In all other forms of production, there is a conflict between the supply of these requirements, since excessive or deficient amounts of one results in an imbalance of one or both of the others. NFT, because of its design, provides a system where all three requirements for healthy plant growth can be met at the same time, provided that the simple concept of NFT is always remembered and practised. The result of these advantages is that higher yields of high-quality produce are obtained over an extended period of cropping.
Sources: en.wikipedia.org
== External links == The MEROPS online database for peptidases and their inhibitors: SPP:A22.003, SPPL2a: A22.007, SPPL2b:A22.004, SPPL2c:A22.006, SPPL3:A22.005 UMich Orientation of Proteins in Membranes families/superfamily-178 - Calculated spatial position of type 1 signal peptidase in membrane signal+peptide+peptidase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Parasitic infestations, stings, and bites in humans are caused by several groups of organisms belonging to the following phyla: Annelida, Arthropoda, Bryozoa, Chordata, Cnidaria, Cyanobacteria, Echinodermata, Nemathelminthes, Platyhelminthes, and Protozoa.
Anthropologists argue that a biomedical focus places emphasis on the biological processes of fixing the body thereby disregarding holistic ideals of health and aging. By relying on a wholly medical approach, Western biomedicine can become blindsided by bodily dysfunctions which can be understood as appropriate functions of age, and not as a medical problem. Anthropologists understand that a biosocial approach to ED considers a person's decision to undergo clinical treatment more likely a result of "society, political economy, history, and culture" than a matter of personal choice. In rejecting biomedical treatment for ED, males can challenge common forms of medicalized social control by deviating from what is considered the normal approach to dysfunction.
== Awards, distinctions and memberships == 2000: Ernst Bloch Promotional Award for his book Gott ist schön. Das ästhetische Erleben des Koran [Godi s Beautiful. The Aesthetic Experience of the Koran] (1999) 2003: Annual Prize of the Helga-und-Edzard-Reuter-Foundation 2004: Schwarzkopf-Europe-Prize of the Foundation Schwarzkopf-Stiftung Junges Europa 2007: Member of the Deutsche Akademie für Sprache und Dichtung 2008: Fellowship of the Villa Massimo in Rom 2009: Hessian Cultural Prize 2011: Nomination of the novel Dein Name for the German Book Prize 2011: Buber-Rosenzweig-Medal 2011: Hannah Arendt Prize; Award Presentation Speech: Marie Luise Knott 2012: Kleist Prize for the novel Dein Name (2011) 2012: Honorary Prize of the City of Cologne Culture Prize Kölner Kulturpreises 2012: Cicero Prize for public speaking 2014: Gerty Spies Literature Prize 2014: Prize of the Association of German Institutions of Dialogue des BDDI 2014: Joseph Breitbach Prize 2015: North Rhine-Westphalian Academy of Sciences, Humanities and the Arts, Member 2015: Peace Prize of the German Publishers' Association 2015: Jan Michalski Prize for Literature finalist for Zwischen Koran und Kafka: West-östliche Erkundungen 2016: Marion Dönhoff Prize for International Understanding and Reconciliation 2017: Hermann Sinsheimer Prize of the City of Freinsheim 2017: ECF Princess Margriet Award for Culture of the European Cultural Foundation 2017: Civic Engagement Award of the German Newspaper Publishers, Award Presentation Speech: Wolf Lepenies 2017: State Prize of the Federal State North Rhine-Westphalia, Award Presentation Speech: Wolfgang Schäuble 2018: Samuel Bogumil Linde Prize; Award Presentation Speech: Joachim Gauck 2020: Friedrich-Hölderlin-Preis 2021: Appointed Honorary Member of the Board of Trustees of the WDR Symphony Orchestra Cologne 2021: Austrian Book Publishers Award for Tolerance in Thought and Action 2022: Honorary Degree of the Philosophy Department of the University of Siegen 2023: Member of the authors association PEN Berlin 2023: Winfried Prize of the City of Fulda 2023: Hans Ehrenberg Prize 2024: Thomas Mann Prize 2026: Bundesverdienstkreuz 1. Klasse
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.